ARTICLE | Company News
Spectrum Pharmaceuticals, Altair deal
February 7, 2005 8:00 AM UTC
Spectrum received exclusive worldwide rights develop and market ALTI's RenaZorb. The lanthanum-based phosphate binding compound is in preclinical development to control phosphate levels in patients w...